Leah Price

ORCID: 0000-0002-5092-4768
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Immunotherapy and Immune Responses
  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • T-cell and B-cell Immunology
  • Cutaneous Melanoma Detection and Management
  • Eosinophilic Disorders and Syndromes
  • Transgenic Plants and Applications
  • Kruppel-like factors research
  • Single-cell and spatial transcriptomics
  • Architecture, Modernity, and Design
  • Computational Drug Discovery Methods
  • Global Cancer Incidence and Screening
  • Multiple Myeloma Research and Treatments
  • Architecture and Computational Design
  • vaccines and immunoinformatics approaches
  • SARS-CoV-2 and COVID-19 Research
  • Molecular Biology Techniques and Applications
  • SARS-CoV-2 detection and testing
  • Empathy and Medical Education
  • Head and Neck Cancer Studies
  • Pregnancy and preeclampsia studies
  • Gestational Diabetes Research and Management
  • Economic and Financial Impacts of Cancer

Israel Institute for Biological Research
2020

New York University
2007-2019

Statistical Research (United States)
2015

Icahn School of Medicine at Mount Sinai
2014

Cancer Research Institute
2013

Clinical Research Consortium
2012

Cancer Research And Biostatistics
2010

Columbia University Irving Medical Center
2009

California Polytechnic State University
2006

Cal Poly Corporation
2006

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) interferon-α (IFN-α) are the most frequently used cytoreductive options ET PV at high risk vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU pegylated IFN-α (PEG) in treatment-naïve, high-risk ET/PV. primary endpoint complete response...

10.1182/blood.2021012743 article EN cc-by-nc-nd Blood 2022-01-10

No consensus has been reached on how to determine if an immune response detected based raw data from ELISPOT assay. The goal of this paper is enable investigators understand and readily implement currently available methods for determination. We describe empirical statistical approaches, identifying the strengths limitations each approach allow readers rationally select apply a scientifically sound method appropriate their specific laboratory setting. Five representative approaches were...

10.1007/s00262-010-0875-4 article EN cc-by-nc Cancer Immunology Immunotherapy 2010-06-14

Abstract BACKGROUND: In patients with multiple primary melanomas (MPM), mean tumor thickness tends to decrease from the first melanoma second melanoma, and prognosis may be improved compared for who have a single (SPM). this study, authors clinicopathologic features of MPM SPM better characterize differences between these 2 groups determine whether or not there is an inherent difference in aggression. METHODS: total, 788 were enrolled prospectively Interdisciplinary Melanoma Cooperative...

10.1002/cncr.27407 article EN Cancer 2012-01-13

Previous results from two proficiency panels of intracellular cytokine staining (ICS) the Cancer Immunotherapy Consortium and National Institute Allergy Infectious Disease Association for highlight variability across laboratories in reported % CD8+ or CD4+ cytokine-positive cells. One main causes interassay flow cytometry-based assays is due to differences gating strategies between laboratories, which may prohibit generation robust within single centers institutions. To study how affect...

10.1002/cyto.a.22319 article EN Cytometry Part A 2013-06-20

Highlights•Ruxolitinib can be integrated as pretransplantation treatment for patients with myelofibrosis.•A tapering strategy before transplantation did not result in any withdrawal-related side effects.•Graft failure and nonrelapse mortality remain significant despite ruxolitinib.AbstractWe evaluated the feasibility of ruxolitinib therapy followed by a reduced-intensity conditioning (RIC) regimen myelofibrosis (MF) undergoing 2-stage Simon phase II trial. The aims were to decrease incidence...

10.1016/j.bbmt.2018.09.001 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2018-09-08

Between April 2020 and March 2021, the number of fall-related emergency admissions in England for adults over 65 years was 1933 per 100 000 people. Adult patients hospital may be at risk falling many reasons including a history falls, being medically unwell, dementia or delirium, effects their treatment medication, poor mobility, visual other sensory impairments along with general well-being. Research has shown that falls can reduced by 20%–30% through multifactorial assessments...

10.1136/bmjoq-2024-003219 article EN cc-by-nc-nd BMJ Open Quality 2025-04-01

The choice of serum for supplementation media T cell assays and in particular, Elispot has been a major challenge assay performance, standardization, optimization, reproducibility. Assay Working Group the Cancer Vaccine Consortium (CVC-CRI) recently identified to be leading cause variability suboptimal performance large international proficiency panels. Therefore, task force was initiated compare commercially available serum-free laboratories' own medium/serum combinations. objective this...

10.1007/s00262-009-0788-2 article EN cc-by-nc Cancer Immunology Immunotherapy 2009-11-05

We performed a multicenter, investigator initiated, phase I dose escalation study of the oral multi-kinase inhibitor lestaurtinib in patients with JAK2V617F positive myelofibrosis, irrespective baseline platelet count. A total 34 were enrolled. Dose-limiting toxicities observed three overall, at 100 mg (n = 1) and 160 2) twice-daily levels. The maximum tolerated was 140 twice daily. Gastrointestinal toxicity most common adverse event. Sixteen evaluable for response 12 weeks. Seven had...

10.3109/10428194.2014.1001986 article EN Leukemia & lymphoma/Leukemia and lymphoma 2015-01-07

Abstract Background The introduction of antibody markers to identify undesired cell populations in flow-cytometry based assays, so called DUMP channel markers, has become a practice an increasing number labs performing HLA-peptide multimer assays. However, the impact assays far not been systematically investigated across broad variety protocols. Methods Cancer Research Institute's Immunotherapy Consortium (CRI-CIC) conducted proficiency panel with specific focus on use. design allowed...

10.1186/1479-5876-9-108 article EN cc-by Journal of Translational Medicine 2011-07-11

Abstract Objectives/Hypothesis: Compliance to intensive multiweek radiation therapy (RT) regimens in head and neck cancer (HNC) patients is challenging, particularly among medically underserved with fewer financial social resources. Treatment prolongation reduces local control overall survival rates, making adherence treatment a key factor optimal outcome. We evaluated factors affecting compliance who received RT for HNC large municipal hospital setting New York City. Study Design:...

10.1002/lary.20963 article EN The Laryngoscope 2010-06-18

The Myeloproliferative Disorder-Research Consortium (MPD-RC) designed the first US prospective phase II study of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis (PMF) or MF secondary to essential thrombocythemia (ET-MF) polycythemia vera (PV-MF). Between May 2007 and March 2011, 66 were enrolled into MPD-RC 101 transplanted from related (n = 32) unrelated 34) donors using a fludarabine/melphalan ± ATG regimen. Of patients, 63...

10.1016/j.bbmt.2011.12.039 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2012-01-10

Results from the first gating proficiency panel of intracellular cytokine staining (ICS) highlighted value using a consensus approach to reduce variability across laboratories in reported %CD8+ or %CD4+ cytokine-positive cells. Based on data analysis panel, harmonization guidelines for protocol were proposed. To validate recommendations and examine factors that not included second ICS was organized. All participants analyzed same set Flow Cytometry Standard (FCS) files their own protocol. An...

10.1002/cyto.a.24244 article EN Cytometry Part A 2020-10-22

Objective: The aim of the project was to identify changes in practice electroconvulsive therapy (ECT) a metropolitan mental health service before and after Mental Health Act 2014 (2014 Act) Victoria. Method: Retrospective clinical file audit ECT administration across all three sites at Eastern (EH) two years introduction Act. Results: There statistically significant decrease number compulsory treatments patients who had hospitals EH following compared prior no difference voluntary ECT....

10.1177/1039856220901466 article EN Australasian Psychiatry 2020-02-04

e16543 Background: Advanced presentation and poor prognosis have been noted for non-white compared to non-Hispanic white melanoma patients. Socioeconomic status (SES) is thought explain this disparity, at least in part. However, the association between SES clinical patients has not yet defined. Methods: Demographic, race insurance information, tumor characteristics, follow-up data were retrieved who presented Bellevue Hospital Center, a public hospital, New York University Cancer Institute...

10.1200/jco.2010.28.15_suppl.e16543 article EN Journal of Clinical Oncology 2010-05-20

In 2005 a total of six Cal Poly students participated in the CRP department´s exchange program with School Architecture and Urbanism at Federal University Rio de Janeiro. This was largest contingent Brazil over single academic year also included from Landscape Department, what proves success this program. Aaron, Karlo Leah, LA student Aron Nussbaum share their thoughts about life experiences Brazil.

10.15368/focus.2006v3n1.15 article EN Focus The Journal of Planning Practice and Education 2006-04-01
Coming Soon ...